The European journal of neuroscienceDec 29, 2025

Type 3 Diabetes: How Brain Insulin Resistance May Link to Nerve Cell Damage Through Sugar-Related Signaling

Alzheimers & Treatments Weekly Brief ↗PubMed ↗DOI ↗

Updated Jan 4, 2026

Abstract

Cerebral insulin resistance may significantly contribute to the progression of Alzheimer's disease (AD) as part of a complex relationship with Type 2 diabetes mellitus (T2DM).

Insulin resistance in the brain disrupts cellular signaling pathways, leading to increased tau hyperphosphorylation and neurofibrillary tangle formation.
Impaired transport of glucose and mitochondrial function can worsen oxidative stress and amyloid-β plaque buildup.
Activation of the AGE-RAGE-NF-κB signaling pathway may heighten neuroinflammation, which is linked to worsened tau and amyloid-β pathology.
Cascades involving MAPK, ERK1/2, and JNK/STAT pathways could promote oxidative stress and further impair brain signaling related to insulin.
Natural bioactive compounds may provide therapeutic benefits by reducing oxidative stress and neuroinflammation associated with AD.
Inhibiting AGE formation or blocking RAGE activation could represent potential strategies to mitigate cognitive decline linked to Type 3 diabetes.

Simplified

Type 3 diabetes, a term that underscores the pathological connection between Type 2 diabetes mellitus (T2DM) and Alzheimer's disease (AD), emphasizes the role of cerebral insulin resistance and metabolic dysfunction in neuron degeneration. Cerebral insulin resistance impairs Akt signaling, leading to the suppression of GSK-3β activity, enhancement of tau hyperphosphorylation and neurofibrillary tangle formation. Concurrent impaired GLUT-3/4 translocation, mitochondrial function, and amyloid-β clearance exacerbate oxidative stress and plaque deposition. Collectively, these disruptions compromise synaptic plasticity and cognition, accelerating AD progression. Moreover, activation of AGE-RAGE-NF-κB signaling amplifies neuroinflammation, further aggravating tau and Aβ pathology. This interaction activates downstream MAPK, ERK1/2, and JNK/STAT pathways, which in turn stimulate transcription factors such as NF-κB, TGF-β, HIF-1α, and AP-1. The resulting cascade promotes oxidative stress, neuroinflammation, and PI3K/Akt/IRS-1 signaling impairment. Together, these interconnected pathways accelerate neuronal loss and cognitive decline. Emerging evidence indicates that natural bioactive compounds offer therapeutic benefits in AD by attenuating AGE-RAGE-mediated oxidative stress, neuroinflammation, and cerebral insulin resistance, thereby reducing amyloid-β accumulation and tau hyperphosphorylation. This review highlights the AGE-RAGE axis as a critical molecular mediator connecting T2DM and AD, orchestrating neuroinflammation, mitochondrial dysfunction, and tau hyperphosphorylation. Therapeutic strategies aimed at inhibiting AGE formation or blocking RAGE activation represent promising approaches to attenuate cognitive decline associated with Type 3 diabetes.

Full Text

Full text is available at the source.

View Full Text ↗

Type 3 Diabetes: How Brain Insulin Resistance May Link to Nerve Cell Damage Through Sugar-Related Signaling

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the alzheimers & treatments brief